Literature DB >> 26992403

Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines.

Zhenyuan Wang1, Chunjun Qin1, Jing Hu1,2, Xiaoqiang Guo1, Jian Yin3.   

Abstract

An effective vaccine for human immunodeficiency virus (HIV) is urgently needed to prevent HIV infection and progression to acquired immune deficiency syndrome (AIDS). As glycosylation of viral proteins becomes better understood, carbohydrate-based antiviral vaccines against special viruses have attracted much attention. Significant efforts in carbohydrate synthesis and immunogenicity research have resulted in the development of multiple carbohydrate-based HIV vaccines. This review summarizes recent advances in synthetic carbohydrate-based vaccines design strategies and the applications of these vaccines in the prevention of HIV.

Entities:  

Keywords:  N-glycosylation; glycoprotein; human immunodeficiency virus (HIV); neutralizing antibodies; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26992403      PMCID: PMC8193421          DOI: 10.1007/s12250-015-3691-3

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  77 in total

Review 1.  Recent advances in carbohydrate-based vaccines.

Authors:  Marie-Lyn Hecht; Pierre Stallforth; Daniel Varón Silva; Alexander Adibekian; Peter H Seeberger
Journal:  Curr Opin Chem Biol       Date:  2009-06-25       Impact factor: 8.822

2.  Selection of a synthetic glycan oligomer from a library of DNA-templated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells.

Authors:  Mihai Ciobanu; Kuo-Ting Huang; Jean-Pierre Daguer; Sofia Barluenga; Olivier Chaloin; Evelyne Schaeffer; Christopher G Mueller; Daniel A Mitchell; Nicolas Winssinger
Journal:  Chem Commun (Camb)       Date:  2011-07-25       Impact factor: 6.222

Review 3.  Antibody recognition of carbohydrate epitopes†.

Authors:  Omid Haji-Ghassemi; Ryan J Blackler; N Martin Young; Stephen V Evans
Journal:  Glycobiology       Date:  2015-06-01       Impact factor: 4.313

4.  Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.

Authors:  Marco Marradi; Paolo Di Gianvincenzo; Pedro M Enríquez-Navas; Olga M Martínez-Ávila; Fabrizio Chiodo; Eloísa Yuste; Jesús Angulo; Soledad Penadés
Journal:  J Mol Biol       Date:  2011-03-25       Impact factor: 5.469

Review 5.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

6.  Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study.

Authors:  Jingsong Wang; Hengguang Li; Guozhang Zou; Lai-Xi Wang
Journal:  Org Biomol Chem       Date:  2007-04-17       Impact factor: 3.876

7.  Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.

Authors:  Lai-Xi Wang; Jiahong Ni; Suddham Singh; Hengguang Li
Journal:  Chem Biol       Date:  2004-01

8.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

9.  Automated solid phase synthesis of oligoarabinofuranosides.

Authors:  Jeyakumar Kandasamy; Mattan Hurevich; Peter H Seeberger
Journal:  Chem Commun (Camb)       Date:  2013-01-31       Impact factor: 6.222

10.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  4 in total

1.  In vitro inhibition of HIV-1 replication in autologous CD4+ T cells indicates viral containment by multifactorial mechanisms.

Authors:  Ting Tu; Jianbo Zhan; Danlei Mou; Wei Li; Bin Su; Tong Zhang; Tao Li; Ning Li; Hao Wu; Cong Jin; Huabiao Chen
Journal:  Virol Sin       Date:  2017-09-15       Impact factor: 4.327

2.  Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies.

Authors:  Sachin S Shivatare; Ting-Jen Rachel Cheng; Yang-Yu Cheng; Vidya S Shivatare; Tsung-I Tsai; Hong-Yang Chuang; Chung-Yi Wu; Chi-Huey Wong
Journal:  ACS Chem Biol       Date:  2021-08-15       Impact factor: 4.634

Review 3.  Recent advances on smart glycoconjugate vaccines in infections and cancer.

Authors:  Marko Anderluh; Francesco Berti; Anna Bzducha-Wróbel; Fabrizio Chiodo; Cinzia Colombo; Federica Compostella; Katarzyna Durlik; Xhenti Ferhati; Rikard Holmdahl; Dragana Jovanovic; Wieslaw Kaca; Luigi Lay; Milena Marinovic-Cincovic; Marco Marradi; Musa Ozil; Laura Polito; Josè Juan Reina; Celso A Reis; Robert Sackstein; Alba Silipo; Urban Švajger; Ondřej Vaněk; Fumiichiro Yamamoto; Barbara Richichi; Sandra J van Vliet
Journal:  FEBS J       Date:  2021-06-01       Impact factor: 5.622

Review 4.  Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines.

Authors:  Sónia Alexandra Correia Carabineiro
Journal:  Molecules       Date:  2017-05-22       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.